Skip to content

Clinical study on chemical ablation of perirenal fat in the treatment of resistant hypertension

Clinical study on chemical ablation of perirenal fat in the treatment of resistant hypertension

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064727
Enrollment
Unknown
Registered
2022-10-15
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

experimental group:chemical ablation

Sponsors

Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years; 2. Hypertensive patients (after applying a reasonable and tolerable sufficient amount of three or more antihypertensive drugs, including diuretics, on the basis of improving their lifestyle) still have a systolic blood pressure of>=150 mmHg but below=90 mmHg or an average ambulatory blood pressure SBP of>=140 mmHg and<170 mmHg.

Exclusion criteria

Exclusion criteria: 1.Secondary hypertension; 2.Estimated glomerular filtration rate,eGFR< 45mL/ (min 1.73m2),renal vascular abnormalities (including severe renal artery stenosis, renal angioplasty or stenting, or known to have double renal arteries); 3.Pregnancy and lactation; 4.A history of myocardial infarction, unstable angina pectoris or cerebrovascular accident in the past 6 months; 5.Uncontrollable bleeding tendency, various active infectious diseases; 6.Those who refuse to sign an informed consent form.

Design outcomes

Primary

MeasureTime frame
ambulatory blood pressure;adverse events;

Countries

China

Contacts

Public ContactZheng Liu

Second Affiliated Hospital of Army Medical University

liuzhengs@163.com+86 13983406200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026